| Symbol | IBIO |
|---|---|
| Name | IBIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 8800 HSC PARKWAY,SUITE 1601, BRYAN, Texas, 77807-1107, United States |
| Telephone | +1 302 355-0650 |
| Fax | — |
| — | |
| Website | https://www.ibioinc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001420720 |
| Description | iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: biologics development and licensing activities, conducted within iBio, Inc. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000935836-26-000283 <b>Size:</b> 19 KB
Read moreNew Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003474 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000935836-26-000266 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002220 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003221 <b>Size:</b> 17 KB
Read moreNew Form 3 - iBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-061762 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001011438-26-000313 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - iBio, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001231919-26-000481 <b>Size:</b> 29 KB
Read more(75% Positive) IBIO, INC. (IBIO) Provides Update on moment for iBio’s evolution as clinical-staged company
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07487376 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Overweight , Obesity | Not_Yet_Recruiting | 2026-04-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT06919354 | A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase1 | Type 1 Diabetes (T1D) | Recruiting | 2025-09-03 | 2028-02-01 | ClinicalTrials.gov |
| NCT06470373 | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascu… | Phase3 | Neovascular Age-related Macular Degeneration (nAMD) | Not_Yet_Recruiting | 2025-07-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT06860516 | HLA Demographics Study in Adults With Type 1 Diabetes | — | Diabetes Mellitus, Type I | Recruiting | 2025-06-06 | 2027-03-01 | ClinicalTrials.gov |
| NCT07024407 | A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Gro… | Phase1 | Heterotopic Ossification (HO) | Recruiting | 2025-05-14 | 2026-01-01 | ClinicalTrials.gov |
| NCT06508021 | A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progres… | Phase2 | Fibrodysplasia Ossificans Progressiva | Active_Not_Recruiting | 2024-10-25 | 2029-02-04 | ClinicalTrials.gov |
| NCT04359472 | The Collection and Application of Autologous Amniotic Fluid At Cesarean Deliver… | Na | Pregnancy Related | Completed | 2020-10-01 | 2024-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| blood draw or cheek swab | Other | Preclinical | Diabetes Mellitus, Type I | RECRUITING | NCT06860516 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| Application of Autologous Amniotic Fluid | Other | Approved | Pregnancy Related | COMPLETED | NCT04359472 |
| Application of Autologous Amniotic Fluid | Other | Approved | Pregnancy Related | COMPLETED | NCT04359472 |
| Eylea® Solution for intravitreal injection | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT06470373 |
| RBS-001 Solution for intravitreal injection | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT06470373 |
| Eylea® Solution for intravitreal injection | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT06470373 |
| RBS-001 Solution for intravitreal injection | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT06470373 |
| Andecaliximab | Other | Phase PHASE1 | Heterotopic Ossification (HO) | RECRUITING | NCT07024407 |
| Andecaliximab | Other | Phase PHASE1 | Heterotopic Ossification (HO) | RECRUITING | NCT07024407 |
| Placebo | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT06508021 |
| Andecaliximab | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT06508021 |
| Placebo | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT06508021 |
| Andecaliximab | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT06508021 |
| Placebo | Other | Phase PHASE1 | Overweight , Obesity | NOT_YET_RECRUITING | NCT07487376 |
| IBIO-600 | Other | Phase PHASE1 | Overweight , Obesity | NOT_YET_RECRUITING | NCT07487376 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| GNTI-122 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | RECRUITING | NCT06919354 |
| Application of Autologous Amniotic Fluid | DEVICE | Approved | Pregnancy Related | COMPLETED | NCT04359472 |
| Placebo | DRUG | Phase PHASE1 | Overweight , Obesity | NOT_YET_RECRUITING | NCT07487376 |
| IBIO-600 | DRUG | Phase PHASE1 | Overweight , Obesity | NOT_YET_RECRUITING | NCT07487376 |